Skip to main content
Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Value Proposition Immune checkpoint inhibitor therapies are exciting new drugs for treatment of cancers. Despite their efficacy for certain cancers, immune checkpoint inhibitors only effective in 10-30% of cancer patients. Because of this, there is…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us